Payment overview · 2025
General Payments
$6,536.70
84 reported records · 24 companies
Healthcare provider profile · identity verified
Marc H. Feinberg, M.D.
Allopathic & Osteopathic Physicians|General Practice · BOCA RATON, FL · NPI 1255422127
Verified facts
What the public records show
CMS Open Payments records show Marc H. Feinberg, M.D. received $6,536.70 in general payments during 2025 across 84 reported records.
Janssen Biotech, Inc. accounted for 70.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ingrezza, Qulipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Ubrelvy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Jardiance by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ingrezza by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MAYZENT as an associated drug or biological on 26 records involving 26 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mayzent by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $4,573.06 | 70.0% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $288.03 | 4.4% | 11 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $212.49 | 3.2% | 9 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $165.64 | 2.5% | 6 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $150.00 | 2.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $137.48 | 2.1% | 6 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $107.08 | 1.6% | 4 | 2025 |
| C2N Diagnostics, LLC | Unresolved — no canonical attribution shown | $102.35 | 1.6% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $100.74 | 1.5% | 4 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $100.35 | 1.5% | 4 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $90.61 | 1.4% | 4 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $75.78 | 1.2% | 3 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $64.96 | 1.0% | 3 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $63.64 | 1.0% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $58.25 | 0.9% | 2 | 2025 |
| InSightec,Inc | Unresolved — no canonical attribution shown | $50.23 | 0.8% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $40.33 | 0.6% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $29.30 | 0.5% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $27.97 | 0.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $22.26 | 0.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $21.72 | 0.3% | 1 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $20.39 | 0.3% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.44 | 0.3% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.60 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $4,035.00 | 2 |
| Food and Beverage | $1,979.31 | 79 |
| Travel and Lodging | $502.00 | 2 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $20.39 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $212.49 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $179.30 | 6 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $165.64 | 6 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $137.48 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $125.26 | 4 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $107.08 | 4 | 2025 |
Source payment records
|
|||||
| PRECIVITYAD2 Normalized: precivityad2 |
Device | C2N Diagnostics, LLC | $102.35 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $100.74 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $100.74 | 4 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $100.35 | 4 | 2025 |
Source payment records
|
|||||
| AMPYRA Normalized: ampyra |
Drug | Merz Pharmaceuticals, LLC | $78.46 | 3 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $78.46 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $75.78 | 3 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $74.66 | 3 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $64.96 | 3 | 2025 |
Source payment records
|
|||||
| FIRDAPSE Normalized: firdapse |
Drug | CATALYST PHARMACEUTICALS, INC. | $63.64 | 1 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $58.25 | 2 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $57.23 | 3 | 2025 |
Source payment records
|
|||||
| Exablate Normalized: exablate |
Device | InSightec,Inc | $50.23 | 2 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $40.33 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $29.30 | 1 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $27.97 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $22.26 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $21.72 | 1 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $16.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | MAYZENT open payments reported associated product |
CMS Open Payments — General Payments 26 supporting records · 26 recipient NPIs · example record 1200006493 |
Mayzent · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Donepezil Hcl | Donepezil Hcl | 427 | 142 |
| Memantine Hcl | Memantine Hcl | 311 | 81 |
| Gabapentin | Gabapentin | 267 | 78 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 230 | 73 |
| Duloxetine Hcl | Duloxetine Hcl | 225 | 82 |
| Primidone | Primidone | 141 | 46 |
| Sertraline Hcl | Sertraline Hcl | 128 | 40 |
| Levetiracetam | Levetiracetam | 116 | 38 |
| Pregabalin | Pregabalin | 100 | 28 |
| Rivastigmine | Rivastigmine | 93 | 27 |
| Emgality Pen | Galcanezumab-Gnlm | 89 | 14 |
| Lacosamide | Lacosamide | 85 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 84 | 28 |
| Clonazepam | Clonazepam | 77 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 70 | 27 |
| Alprazolam | Alprazolam | 60 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 59 | 24 |
| Mirtazapine | Mirtazapine | 56 | 18 |
| Prednisone | Prednisone | 54 | 13 |
| Propranolol Hcl Er | Propranolol Hcl | 53 | 19 |
| Rytary | Carbidopa/Levodopa | 51 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 39 | 12 |
| Buspirone Hcl | Buspirone Hcl | 38 | 12 |
| Lamotrigine | Lamotrigine | 37 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 36 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Topiramate | Topiramate | 31 | 11 |
| Baclofen | Baclofen | 28 | suppressed |
| Galantamine Er | Galantamine Hbr | 28 | 14 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 28 | 12 |
| Temazepam | Temazepam | 27 | suppressed |
| Ubrelvy | Ubrogepant | 26 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 23 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 19 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 19 | suppressed |
| Ramelteon | Ramelteon | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 16 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 16 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | 11 |
| Qulipta | Atogepant | 16 | suppressed |
| Carbamazepine Er | Carbamazepine | 15 | suppressed |
| Simvastatin | Simvastatin | 14 | suppressed |
| Copaxone | Glatiramer Acetate | 13 | suppressed |
| Mayzent | Siponimod | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | suppressed |
| Ingrezza | Valbenazine Tosylate | 12 | suppressed |
| Kesimpta Pen | Ofatumumab | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 11 | suppressed |
| Jardiance | Empagliflozin | 11 | suppressed |
| Xcopri | Cenobamate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $6,536.70 · 84 records | Janssen Biotech, Inc. | AMPYRA, AUSTEDO XR, BOTOX, Exablate, FIRDAPSE, HYQVIA, Hizentra, INBRIJA, INGREZZA, KESIMPTA, KISUNLA, NURTEC ODT, ONPATTRO, Ocrevus Zunovo, PONVORY, PRECIVITYAD2, QULIPTA, TYSABRI, UBRELVY, ULTOMIRIS, UPLIZNA, VYALEV, VYEPTI, VYVGART HYTRULO, Xeomin, ZAVZPRET, Zilbrysq | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ingrezza play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error